ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

Core Insights - ZyVersa Therapeutics, Inc. is developing a novel drug, Inflammasome ASC Inhibitor IC 100, targeting extracellular ASC to mitigate chronic inflammatory conditions associated with amyloid A amyloidosis [2][3][5] - Recent research published in EMBO Molecular Medicine highlights the role of extracellular ASC in the aggregation and deposition of amyloid A fibrils, which are linked to various chronic inflammatory diseases [2][3] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a significant market opportunity exceeding $100 billion [6][7] - The lead indication for IC 100 is obesity and its related metabolic complications, while another product, VAR 200, targets focal segmental glomerulosclerosis (FSGS) [7] Research Findings - The study indicates that ASC colocalizes with serum amyloid A (SAA) in human AA amyloidosis and that ASC specks accelerate SAA fibril formation [3][4] - In a Pycard knock-out mouse model lacking ASC, splenic amyloid load was significantly decreased, suggesting the importance of ASC in amyloid deposition [3] - Treatment with anti-ASCPYD antibodies resulted in reduced amyloid loads in wild-type mice with AA amyloidosis, supporting the therapeutic potential of targeting ASC [3][4] Product Mechanism - IC 100 is a humanized IgG4 monoclonal antibody designed to inhibit the inflammasome adaptor protein ASC, thereby reducing both the initiation and perpetuation of inflammatory responses [5] - The mechanism involves binding to ASC in various inflammasomes, blocking IL-1β activation, and attenuating the adaptive immune response [5]